Toulouse

• TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II t … Recruiting
  2023-510568-11-00 9 2025-11-18 High grade brain tumors
• A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting
  2024-517553-26-00 5 2025-11-12 Advanced ALK-positive non-small cell lung cancer (NSCLC)
• A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting
  2024-518008-33-00 5 2025-11-12 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
• IFCT-2401 SPORADIC a multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequ … Recruiting
  2024-517316-29-00 4 2025-11-07 Unresectable stage III Non-Small Cell Lung Cancer
• AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe … Recruiting
  2023-506843-40-00 5 2025-10-29 Mycobacterium xenopi pulmonary infection
• Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting
  2025-520694-39-00 4 2025-10-24 Metastatic or locally advanced irresectable (stage IV) gastric cancer
• A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antim … Recruiting
  2024-517140-65-00 9 2025-10-23 Multiple Myeloma (MM).
• Durvalumab and tremelimumab with or without Hepatic Arterial Infusion of gemcitabine and oxaliplatin in hepatocellular carcinoma patients. Recruiting
  2024-514912-28-00 10 2025-10-22 Patients with hepatocellular carcinoma with high tumor burden.
• A randomized, parallel-arm, double blind, placebo-controlled study to assess the efficacy of fampridine for patients with spinocerebellar at … Recruiting
  2024-520413-53-00 5 2025-10-21 Spinocerebellar ataxia
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid … Recruiting
  2025-520564-17-00 5 2025-10-16 Hidradenitis suppurativa (HS)
• Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un c … Recruiting
  2025-522656-68-00 6 2025-10-15 Metastatic breast cancers
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o … Recruiting
  2023-509275-17-00 5 2025-10-06 Relapsing multiple sclerosis
• A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients … Recruiting
  2024-514152-32-00 3 2025-10-06 Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)
• Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis Recruiting
  2024-511871-13-00 6 2025-10-02 Postmenopausal osteoporosis
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 Recruiting
  2024-511989-36-00 5 2025-09-24 Ewing Sarcoma
• A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting
  2024-520386-31-00 5 2025-09-22 Locally Advanced Head & Neck Squamous Cell Carcinoma
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS2) Recruiting
  2024-517633-40-00 5 2025-09-18 Hidradenitis Suppurativa
• A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting
  2024-513171-41-00 5 2025-09-11 Vitiligo
• Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting
  2024-518325-15-00 5 2025-09-08 Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
• A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting
  2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease

Showing 169–192 of 642 trials